SAB Biotherapeutics (SABS) AI Stock Analysis

• Market Cap: $18.21M
• Dividend Yield: N/A
• Average Volume (3M): 35.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.69
• Revenue Growth: -85.48%
• EPS Growth: 45.13%
• Country: US
• Employees: 63
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 9,291,697
• 10 Day Avg. Volume: 9,279
• 30 Day Avg. Volume: 35,131
• PEG Ratio: 0.00
• Price to Book (P/B): -1.91K
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -449.21
• Enterprise Value/Market Cap: 242.37
• Enterprise Value/Revenue: 736.56
• Enterprise Value/Gross Profit: -3.09K
• Enterprise Value/Ebitda: -32.77
• 1Y Price Target: $6.00
• Price Target Upside: 132.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 52 Neutral
• Price Target: $2.50 ▼(-3.10%Downside)

SAB Biotherapeutics' overall score is primarily impacted by its financial performance, which presents significant challenges due to declining revenues and persistent losses. Although technical analysis indicates positive momentum, the stock's valuation is limited by a negative P/E ratio. The lack of recent earnings call data and corporate events leaves the financial performance and technical analysis as primary determinants of the score.

Positive Factors

Clinical Development Progress

The Phase 2b SAFEGUARD study in adult and pediatric patients with new-onset stage 3 T1D is anticipated to initiate in mid-2025, indicating progress in clinical development.

Competitive Advantage

SAB-142 has a potential competitive dosing regimen with 2-3 days dosing versus 12-14 days with teplizumab, which could be advantageous for outpatient settings.

Safety Profile

SAB-142 was generally well tolerated among healthy volunteers, with most adverse events being mild and resolving quickly, and no drug-related serious adverse events reported.

Negative Factors

Market Risks

The company's plans to potentially pursue other indications for SAB-142 in different stages of type 1 diabetes suggest a broader market opportunity but also introduce the risk of diluting focus and resources.

SAB Biotherapeutics Business Overview & Revenue Model

Company Description

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

How the Company Makes Money

SAB Biotherapeutics generates revenue primarily through research and development collaborations, government contracts, and grants. The company's revenue streams include milestone payments from strategic partnerships and licensing agreements, where they collaborate with pharmaceutical companies and government agencies to develop and commercialize their antibody-based therapies. Additionally, SAB Biotherapeutics may receive revenue from the sale of its therapeutic products once they gain regulatory approval and enter the market.

SAB Biotherapeutics Financial Statement Overview

Summary

SAB Biotherapeutics faces significant financial challenges, including a dramatic decline in revenue and persistent losses. The cash flow issues and a high debt-to-equity ratio exacerbate concerns, although the balance sheet provides a modicum of stability.

Income Statement

SAB Biotherapeutics has experienced a significant decline in revenue over recent years, with total revenue falling from $60.88 million in 2021 to just $1.32 million in 2024. The company has maintained negative EBIT and net income, indicating ongoing operational challenges. Margins have remained weak, with a negative net profit margin, reflecting persistent losses.

Balance Sheet

The company's balance sheet shows a relatively high debt-to-equity ratio, indicating a reliance on debt financing. However, the equity ratio remains reasonable, suggesting some level of financial stability. Stockholders' equity has decreased over the years, which could be a concern if this trend continues.

Cash Flow

SAB Biotherapeutics has faced challenges in generating positive operating cash flow, with significant negative free cash flow in recent years. The company has also shown volatility in financing cash flows, suggesting potential difficulties in maintaining liquidity and funding operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	377.83K	1.32M	2.24M	23.90M	60.88M	55.24M
Gross Profit	-1.43M	-3.47M	-1.51M	20.61M	59.22M	55.24M
EBITDA	-30.38M	-28.99M	-38.13M	-15.12M	-15.20M	21.14M
Net Income	-34.28M	-34.10M	-42.19M	-18.74M	-17.14M	20.12M
Balance Sheet
Total Assets	38.12M	44.20M	83.94M	50.90M	79.37M	56.54M
Cash, Cash Equivalents and Short-Term Investments	12.85M	20.76M	56.57M	15.05M	33.21M	12.61M
Total Debt	6.78M	4.67M	5.91M	5.93M	6.74M	8.13M
Total Liabilities	16.71M	18.23M	26.64M	19.85M	40.82M	17.53M
Stockholders Equity	21.41M	25.97M	57.30M	31.06M	38.55M	39.01M
Cash Flow
Free Cash Flow	-31.62M	-34.63M	-25.32M	-7.19M	-7.19M	-2.73M
Operating Cash Flow	-31.41M	-34.29M	-25.12M	3.76M	3.76M	10.00M
Investing Cash Flow	24.07M	-11.96M	-152.70K	-10.94M	-10.94M	-12.72M
Financing Cash Flow	-952.19K	-1.17M	66.77M	34.12M	34.12M	8.98M

SAB Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.58
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SABS, the sentiment is Positive. The current price of 2.58 is above the 20-day moving average (MA) of 1.83, above the 50-day MA of 1.81, and above the 200-day MA of 2.43, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 79.34 is Negative, neither overbought nor oversold. The STOCH value of 62.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SABS.

SAB Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SABS	52 Neutral	$18.21M	―	-92.35%	―	-85.48%	45.13%
Sector *	52 Neutral	$7.45B	0.27	-61.87%	2.30%	16.62%	1.04%
IMNN	41 Neutral	$14.83M	―	-397.54%	―	―	24.16%
ERNA		$13.47M	―	-2264.31%	―	―	―
BOLT	45 Neutral	$11.25M	―	-83.92%	―	-67.87%	0.40%
MRKR	44 Neutral	$17.76M	―	-97.30%	―	-3.23%	38.05%
INAB	34 Underperform	$7.23M	―	-174.66%	―	―	38.53%